BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35410757)

  • 41. A systematic review of outcomes after stem cell transplantation in acute lymphoblastic leukemia with or without measurable residual disease.
    Shah S; Martin A; Turner M; Cong Z; Zaman F; Stein A
    Leuk Lymphoma; 2020 May; 61(5):1052-1062. PubMed ID: 31960716
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy.
    Gu J; Liu S; Cui W; Dai H; Cui Q; Yin J; Li Z; Kang L; Qiu H; Han Y; Miao M; Chen S; Xue S; Wang Y; Jin Z; Zhu X; Yu L; Wu D; Tang X
    Front Immunol; 2022; 13():858590. PubMed ID: 35371098
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relapsed ALL: CAR T vs transplant vs novel therapies.
    Frey NV
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):1-6. PubMed ID: 34889387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
    Mannis GN; Martin TG; Damon LE; Andreadis C; Olin RL; Kong KA; Faham M; Hwang J; Ai WZ; Gaensler KML; Sayre PH; Wolf JL; Logan AC
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1030-1036. PubMed ID: 26899561
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.
    Jacoby E; Bielorai B; Avigdor A; Itzhaki O; Hutt D; Nussboim V; Meir A; Kubi A; Levy M; Zikich D; Zeltzer LA; Brezinger K; Schachter J; Nagler A; Besser MJ; Toren A
    Am J Hematol; 2018 Dec; 93(12):1485-1492. PubMed ID: 30187944
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia.
    Xie L; Ma L; Liu S; Chang L; Wen F
    Int Immunopharmacol; 2021 Jul; 96():107731. PubMed ID: 33965880
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insights from the Greek experience of the use of Blinatumomab in pediatric relapsed and refractory acute lymphoblastic leukemia patients.
    Ampatzidou M; Kattamis A; Baka M; Paterakis G; Anastasiou T; Tzanoudaki M; Kaisari A; Avgerinou G; Doganis D; Papadakis V; Kitra V; Polychronopoulou S
    Neoplasma; 2020 Nov; 67(6):1424-1430. PubMed ID: 32701357
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
    Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation.
    Marra JD; Galli E; Giammarco S; Metafuni E; Minnella G; Fosso F; Marietti S; Sica S; Sorà F; Chiusolo P
    Eur J Haematol; 2024 Jul; 113(1):127-129. PubMed ID: 38644613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia.
    Baek DW; Lee JM; Kim J; Cho HJ; Moon JH; Sohn SK
    Expert Rev Hematol; 2021 Aug; 14(8):765-775. PubMed ID: 34313508
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Aldoss I; Stiller T; Cao TM; Palmer JM; Thomas SH; Forman SJ; Pullarkat V
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1326-9. PubMed ID: 25842050
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.
    Czyz A; Nagler A
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661875
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
    Liu J; Zhang X; Zhong JF; Zhang C
    Immunotherapy; 2019 Jan; 11(1):37-44. PubMed ID: 30702011
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Chimeric antigen receptors T cells in treatment of a relapsed pediatric acute lymphoblastic leukemia, relapse after allogenetic hematopoietic stem cell transplantation: case report and review of literature review].
    Zuo Y; Wang J; Lu A; Jia Y; Wu J; Dong L; Chang L; Zhang L
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):115-8. PubMed ID: 27014980
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.
    Friend BD; Bailey-Olson M; Melton A; Shimano KA; Kharbanda S; Higham C; Winestone LE; Huang J; Stieglitz E; Dvorak CC
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28079. PubMed ID: 31724815
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study.
    Yang J; He J; Zhang X; Li J; Wang Z; Zhang Y; Qiu L; Wu Q; Sun Z; Ye X; Yin W; Cao W; Shen L; Sersch M; Lu P
    Blood Cancer J; 2022 Jul; 12(7):104. PubMed ID: 35798714
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia.
    Senapati J; Kantarjian H; Haddad FG; Short NJ; Welch MA; Jain N; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):333-339. PubMed ID: 38195323
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions.
    Varadarajan I; Pierce E; Scheuing L; Morris A; El Chaer F; Keng M
    Onco Targets Ther; 2023; 16():1-16. PubMed ID: 36685611
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.